reported net income for the third quarter was $num-one billion, and diluted earnings per share were $num-two.
we are now guiding full year year-six non-gaap currency-neutral revenue growth to be between num-one% and num-two% versus our prior guidance of num-three% to num-four%.
net sales for the third quarter of year-six were $num-one million, which is a num-two% increase on a reported basis versus the $num-three million in qtr-three of year-five.
and finally, non-gaap net income for the third quarter of year-six was $num-one million or $num-two diluted earnings per share, and that compares to $num-three million and $num-four per share in qtr-three of year-five.
full year covid-related sales are now expected in the range of $num-one million and $num-two million versus our prior guidance of $num-three million to $num-four million.
on a currency-neutral basis, sales increased num-one%.
qtr-three operating income was $num-one million or num-two% of sales compared to $num-three million or num-four% of sales in qtr-three of year-five.
sales of the life science group in the third quarter of year-six were $num-one million compared to $num-two million in qtr-three of year-five, which is a num-three% increase on a reported basis and a num-four% increase on a currency-neutral basis.
sales of the clinical diagnostics group in the third quarter were $num-one million compared to $num-two million in qtr-three of year-five, which is a num-three% increase on a reported basis and a num-four% increase on a currency-neutral basis.
these exclusions moved the gross margin for the third quarter of year-six to a non-gaap gross margin of num-one% versus num-two% in qtr-three of year-five.
research and development expense in qtr-three was $num-one million or num-two% of sales compared to $num-three million or num-four% of sales in qtr-three of year-five.
sg&a expenses for qtr-three of year-six were $num-one million or num-two% of sales compared to $num-three million or num-four% in qtr-three of year-five.
full year non-gaap gross margin is now projected to be between num-one% and num-two% versus prior guidance of num-three% and num-one%.
excluding the $num-one million settlement for back royalties, the underlying life science business grew num-two% on a currency-neutral basis versus qtr-three of year-five.
full year adjusted ebitda margin is now forecasted to be between num-one% and num-two% versus prior guidance of num-three% and num-one%.
we see dropworks as accelerating bio-rad's entry into the lower-end segment of the digital pcr business and allow for expansion in the $num-one billion to $num-two billion qpcr segment, thereby significantly increasing the opportunity for our ddpcr platforms.